Jeremy Ross

Company: Abbvie

Job title: Director & Head of Precision Medicine, Hematology Scientific Oncology

Seminars:

Delving into ABBV-383, a Novel Bispecific Antibody with Enhanced Tumor Targeting & Optimized T-cell Engagement in Multiple Myeloma 9:30 am

Scientific rationale for high avidity tumor antigen binding coupled with low affinity CD3 T-cell engagement by ABBV-383 Translation of unique design attributes of ABBV-383 to the clinic Clinical updates on ABBV-383 in patient with relapsed or refractory multiple myelomaRead more

day: Day One